This analysis examines the global genetic testing industry (specifically, germline genetic testing, which analyzes inherited genetic variations present in an individual from birth and can be passed to offspring). This industry’s growth is driven by a shift towards preventive care, rising maternal ages, increasing government support for early screening, declining sequencing costs, expanding payer coverage, emerging pharmacogenomics, accelerating technology adoption, and increasing clinical integration.

It categorizes the industry by application, which includes prenatal screening, newborn screening, predictive or presymptomatic testing, and other segments (preimplantation genetic testing in IVF, forensic and identity testing, and diagnostic gene panels for complex syndromes such as epilepsy and autism). It also provides a 6-year revenue forecast and an analysis of key industry participants. Regional analyses are provided for North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America.

• What growth opportunities arise from the widespread deployment of genetic testing across hospitals, diagnostic labs, specialty clinics, fertility centers, public health bodies, and more?
• How can vendors leverage innovation in DNA sequencing platforms, assay kits, consumables, reagents, and bioinformatics for revenue growth?
• How can your team harness AI-based interpretation, next-generation sequencing (NGS), and clustered regularly interspaced short palindromic repeats (CRISPR) technologies to gain an edge in the genetic testing industry?